




Strontium Chloride Sr 89

Revised: December 3, 2018.

CASRN: 38270-90-5



Drug Levels and Effects

Summary of Use during Lactation

Information in this record refers to the use of strontium 89 as a therapeutic agent. No information is available on the therapeutic use of strontium 89 during breastfeeding. It has been estimated that about 9% of the strontium in the maternal bloodstream reaches breastmilk for another strontium isotope, strontium 90.[1] Because strontium can substitute for calcium in infant bones, the manufacturer and expert opinion recommend discontinuing breastfeeding before a nursing mother receives strontium 89 chloride.[2]

Drug Levels

Strontium 89 decays by beta emission with a physical half-life of 50.5 days.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1. Harrison JD, Smith TJ, Phipps AW. Infant doses from the transfer of radionuclides in mothers' milk. *Radiat Prot Dosimetry*. 2003;105:251-6. PubMed PMID: 14526966.
2. Bodei L, Lam M, Chiesa C et al. EANM procedure guideline for treatment of refractory metastatic bone pain. *Eur J Nucl Med Mol Imaging*. 2008;35:1934-40. PubMed PMID: 18649080.

Substance Identification

Substance Name

Strontium Chloride Sr 89

CAS Registry Number

38270-90-5

Drug Class

Breast Feeding

Lactation

Radiopharmaceuticals

Strontium Radioisotopes